$6.59
Live
1.06%
Downside
Day's Volatility :12.37%
Upside
11.42%
82.47%
Downside
52 Weeks Volatility :84.18%
Upside
9.73%
Period | Alpha Teknova Inc | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 221.15% | 3.6% | 0.0% |
6 Months | 264.5% | 10.2% | 0.0% |
1 Year | 245.5% | 19.6% | 0.0% |
3 Years | -69.21% | 16.8% | -23.0% |
Market Capitalization | 345.8M |
Book Value | $1.94 |
Earnings Per Share (EPS) | -0.92 |
Wall Street Target Price | 5.5 |
Profit Margin | -98.08% |
Operating Margin TTM | -53.05% |
Return On Assets TTM | -15.1% |
Return On Equity TTM | -41.51% |
Revenue TTM | 34.9M |
Revenue Per Share TTM | 0.92 |
Quarterly Revenue Growth YOY | -16.6% |
Gross Profit TTM | 17.5M |
EBITDA | -23.4M |
Diluted Eps TTM | -0.92 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.55 |
EPS Estimate Next Year | -0.42 |
EPS Estimate Current Quarter | -0.16 |
EPS Estimate Next Quarter | -0.15 |
What analysts predicted
Downside of 16.54%
FY19 | Y/Y Change | |
---|---|---|
Revenue | 20.1M | - |
Net Income | -1.3M | - |
Net Profit Margin | -6.49% | - |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 31.3M | ↑ 55.75% |
Net Income | 3.6M | ↓ 373.56% |
Net Profit Margin | 11.41% | ↑ 17.9% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 36.9M | ↑ 17.88% |
Net Income | -9.8M | ↓ 374.59% |
Net Profit Margin | -26.57% | ↓ 37.98% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 41.4M | ↑ 12.27% |
Net Income | -47.5M | ↑ 384.22% |
Net Profit Margin | -114.6% | ↓ 88.03% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 36.7M | ↓ 11.43% |
Net Income | -36.8M | ↓ 22.52% |
Net Profit Margin | -100.26% | ↑ 14.34% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 9.1M | ↑ 15.59% |
Net Income | -8.8M | ↓ 33.68% |
Net Profit Margin | -96.67% | ↑ 71.8% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 11.5M | ↑ 26.38% |
Net Income | -7.2M | ↓ 18.86% |
Net Profit Margin | -62.06% | ↑ 34.61% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 8.2M | ↓ 29.13% |
Net Income | -10.2M | ↑ 41.92% |
Net Profit Margin | -124.29% | ↓ 62.23% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 7.9M | ↓ 3.7% |
Net Income | -10.7M | ↑ 4.95% |
Net Profit Margin | -135.45% | ↓ 11.16% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 9.3M | ↑ 18.09% |
Net Income | -8.1M | ↓ 24.01% |
Net Profit Margin | -87.16% | ↑ 48.29% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Revenue | 9.6M | ↑ 3.49% |
Net Income | -5.4M | ↓ 33.75% |
Net Profit Margin | -55.79% | ↑ 31.37% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 58.5M | - |
Total Liabilities | 45.6M | - |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 62.9M | ↑ 7.52% |
Total Liabilities | 46.1M | ↑ 1.19% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 166.5M | ↑ 164.68% |
Total Liabilities | 23.3M | ↓ 49.49% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 152.3M | ↓ 8.56% |
Total Liabilities | 52.4M | ↑ 124.71% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 128.6M | ↓ 15.55% |
Total Liabilities | 38.6M | ↓ 26.4% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 141.0M | ↓ 7.38% |
Total Liabilities | 48.9M | ↓ 6.57% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 132.5M | ↓ 6.01% |
Total Liabilities | 46.3M | ↓ 5.3% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 138.4M | ↑ 4.4% |
Total Liabilities | 38.7M | ↓ 16.42% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 128.6M | ↓ 7.08% |
Total Liabilities | 38.6M | ↓ 0.47% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 120.8M | ↓ 6.04% |
Total Liabilities | 37.4M | ↓ 2.88% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 115.4M | ↓ 4.52% |
Total Liabilities | 36.4M | ↓ 2.71% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 2.2M | - |
Investing Cash Flow | -8.4M | - |
Financing Cash Flow | 8.6M | - |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 2.5M | ↑ 15.33% |
Investing Cash Flow | -1.7M | ↓ 79.24% |
Financing Cash Flow | -1.6M | ↓ 118.66% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -9.1M | ↓ 462.04% |
Investing Cash Flow | -17.5M | ↑ 909.86% |
Financing Cash Flow | 110.8M | ↓ 7028.89% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -27.4M | ↑ 202.13% |
Investing Cash Flow | -28.1M | ↑ 60.66% |
Financing Cash Flow | 10.3M | ↓ 90.73% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -7.7M | ↓ 4.3% |
Investing Cash Flow | -4.3M | ↓ 8.84% |
Financing Cash Flow | -25.0K | ↓ 100.49% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -3.9M | ↓ 49.82% |
Investing Cash Flow | -2.3M | ↓ 45.78% |
Financing Cash Flow | -180.0K | ↑ 620.0% |
Sell
Neutral
Buy
Alpha Teknova Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Alpha Teknova Inc | 48.78% | 264.5% | 245.5% | -69.21% | -69.33% |
Neurocrine Biosciences Inc. | 0.22% | -11.71% | 9.36% | 13.47% | 21.32% |
Haleon Plc Spon Ads | -5.08% | 20.69% | 22.01% | 36.17% | 36.17% |
Zoetis Inc. | -0.16% | 32.8% | 16.08% | -7.35% | 52.85% |
Viatris Inc. | 2.53% | 4.53% | 31.84% | -16.06% | -28.03% |
Catalent, Inc. | 0.9% | 7.56% | 42.8% | -54.43% | 23.98% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Alpha Teknova Inc | NA | NA | NA | -0.55 | -0.42 | -0.15 | NA | 1.94 |
Neurocrine Biosciences Inc. | 35.55 | 35.55 | 0.27 | 4.54 | 0.16 | 0.12 | NA | 24.87 |
Haleon Plc Spon Ads | 32.52 | 32.52 | 1.5 | 0.39 | 0.07 | 0.04 | 0.02 | 1.82 |
Zoetis Inc. | 37.9 | 37.9 | 2.64 | 5.83 | 0.49 | 0.14 | 0.01 | 10.94 |
Viatris Inc. | 224.4 | NA | 0.07 | 2.67 | -0.03 | 0.03 | 0.04 | 16.36 |
Catalent, Inc. | 211.02 | NA | 3.02 | 0.2 | -0.25 | 0.0 | NA | 19.91 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Alpha Teknova Inc | Buy | $345.8M | -69.33% | NA | -98.08% |
Neurocrine Biosciences Inc. | Buy | $11.9B | 21.32% | 35.55 | 16.0% |
Haleon Plc Spon Ads | Buy | $45.6B | 36.17% | 32.52 | 9.66% |
Zoetis Inc. | Buy | $87.6B | 52.85% | 37.9 | 26.29% |
Viatris Inc. | Hold | $14.0B | -28.03% | 224.4 | -4.24% |
Catalent, Inc. | Hold | $10.9B | 23.98% | 211.02 | -23.81% |
Insights on Alpha Teknova Inc
Revenue is up for the last 3 quarters, 7.86M → 9.61M (in $), with an average increase of 9.3% per quarter
Netprofit is up for the last 3 quarters, -10.65M → -5.36M (in $), with an average increase of 41.3% per quarter
In the last 3 years, Alpha Teknova Inc has experienced a drawdown of -69.2%, however Neurocrine Biosciences Inc. resisted the overall trend and outperformed by 14.8%
Millennium Management LLC
Balyasny Asset Management LLC
Vanguard Group Inc
Junked Platinum Investment Management Ltd
Conestoga Capital Advisors, LLC
Parkman Healthcare Partners LLC
teknova makes prepared media for bacteria and yeast applications. we have a full portfolio that includes plated and liquid growth media, as well as dry microbiological media that is available both bottled and in our propietary soluble pouch. we also have a full range of buffers, reagents and solutions, and everything we carry is available in custom formulations in order to optimize our products specifically to each of our customer's application. we have done it all before, and we challenge our customers to come up with a formulation that is a first time request.
Organization | Alpha Teknova Inc |
Employees | 210 |
CEO | Mr. Stephen Gunstream |
Industry | Healthcare |